ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RGN Regenerx Biopharmaceuticals

0.00
0.00 (0.00%)
Pre Market
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regenerx Biopharmaceuticals AMEX:RGN AMEX Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

RegeneRx Announces TB4 Stroke Study to be Honored at American Heart Association Scientific Sessions

14/09/2010 2:08pm

Business Wire


Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Regenerx Biopharm In Charts.

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) today announced that the abstract entitled Treatment of Acute Stroke With Thymosin β4 has been honored with a score in the top 10 percent of all abstracts presented at the American Heart Association’s specialty conferences during the year, and therefore has been selected for re-presentation as a poster at the AHA’s Scientific Sessions on November 15. The Scientific Sessions will be held in Chicago from November 13 through 17.

“We congratulate Dr. Daniel C. Morris, senior staff physician, Department of Emergency Medicine, Henry Ford Health Systems and his team on this recognition of their important work,” said J.J. Finkelstein, president and chief executive of RegenerRx. “With more than 20,000 attendees at this significant conference, this poster presentation will provide greater visibility and broader reach for the potential use of Tβ4 to treat stroke. This exposure is particularly welcome at this time as we formulate our plans to advance Tβ4 into the clinic for various CNS indications and hold strategic partnership discussions,” Mr. Finkelstein added.

The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System and was originally presented at the International Stroke Conference, San Antonio, TX, in February of this year. Dr. Morris and his researchers showed that TB4, administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals. Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant.

About Tβ4

Tβ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-functional molecule that has been shown in pre-clinical studies to promote progenitor and endothelial cell differentiation and migration in the heart and central nervous system, promote cardiac and neuronal repair, angiogenesis in dermal and cardiac tissues, increase keratinocyte migration and collagen deposition, and decrease inflammation by down-regulating inflammatory cytokines. RegeneRx has identified several molecular variations of Tβ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health and various academic researchers throughout the world have published numerous scientific articles in high impact journals indicating Tβ4’s in vitro and in vivo efficacy in accelerating wound healing and tissue protection and regeneration under a variety of conditions. Abstracts of scientific papers related to Tβ4’s mechanisms of action can be viewed at www.regenerx.com.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. Currently RegeneRx has three products in clinical development. RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352. RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. RegeneRx is currently supporting a physician-sponsored Phase 2 dry eye study evaluating RGN-259. RGN-137, a topical gel formulation, is currently being evaluated by RegeneRx in a Phase 2 clinical trial for the treatment of epidermolysis bullosa. Other potential uses for RGN-137 include the treatment of chronic dermal wounds and reduction of scar tissue. Based on strong efficacy data in pre-clinical studies, RegeneRx is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction, or heart attack. In addition to this indication, recent pre-clinical efficacy data suggests that RGN-352 may also benefit patients with multiple sclerosis and stroke. RegeneRx also has a preclinical product candidate, RGN-457, which is an inhaled formulation targeting cystic fibrosis and other pulmonary diseases. In addition to the four pharmaceutical product candidates described above, RegeneRx is pursuing the commercial development of peptide fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds 75 issued patents and has 261 patent applications pending worldwide related to its products and holds an exclusive worldwide license for Tβ4 from the National Institutes of Health.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” ”may,” “potential” or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risk that our product candidates do not demonstrate safety and/or efficacy in future clinical trials; risks related to our ability to obtain financing to support our operations on commercially reasonable terms; the progress, timing or success of our clinical trials; difficulties or delays in development, testing, obtaining regulatory approval for producing and marketing our product candidates; regulatory developments; the size and growth potential of the markets for our product candidates and our ability to serve those markets; the scope and validity of patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” sections of the annual report on Form 10-K for the year ended December 31, 2009, and the quarterly report on Form 10-Q for the quarter ended June 30, 2010, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

1 Year Regenerx Biopharm In Chart

1 Year Regenerx Biopharm In Chart

1 Month Regenerx Biopharm In Chart

1 Month Regenerx Biopharm In Chart

Your Recent History

Delayed Upgrade Clock